Why the study?
Premature ventricular complexes are prevalent and often benign, but they can signify underlying heart disease, cause left ventricular dysfunction, or rarely cause sudden cardiac death, requiring guidance on risk stratification and treatment.
When and how should premature ventricular complexes be evaluated and treated?
When and how should premature ventricular complexes be evaluated and treated?
This review outlines the evaluation and management of premature ventricular complexes, focusing on risk stratification and indications for therapy.
May guide PVC risk stratification in practice; leaves open optimal thresholds pending prospective validation.
Premature ventricular complexes (PVCs) are prevalent arrhythmias and a common reason for cardiac consultation. While often benign, PVCs can be markers of underlying heart disease and result in significant symptoms, left ventricular dysfunction, and in rare cases sudden cardiac death. The evaluation of a patient with PVCs should answer two essential questions: ( a ) Is the arrhythmia benign or it is a manifestation of a more serious heart condition? ( b ) Does the patient require specific therapy to suppress the PVCs? This review focuses on risk stratification of patients to identify who may benefit from further evaluation and the clinical scenarios wherein treatment of PVCs should be considered.
No takes yet. Share an insight, caveat, or question.
Enríquez et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: